Goldman Sachs initiated coverage on ResMed Inc (NYSE:RMD) with a "Buy" rating and a price target of A$48.9, driven by strong growth prospects in its continuous airway pressure (CPAP) therapy segment.

The note reveals that Goldman has initiated coverage with a buy rating and $48.90 price target on ResMed's shares. Based on ...

OSA impacts about 936 million people worldwide and occurs when the throat muscles relax and block the airway with a common ...

Adam Maeder, an analyst from Piper Sandler, has initiated a new Hold rating on Resmed (RMD).Stay Ahead of the Market:Discover outperforming ...

ResMed launches AirSense 11, to advance digital health in sleep apnoea for Indians: Our Bureau, Bengaluru Monday, January 6, 2025, 17:30 Hrs [IST] ResMed, the world’s leading he ...

ResMed actually specializes in ventilators, for example against sleep apnoea. Now comes the first end customer product for ...

These 2 ASX shares are set to deliver a strong set of earnings in the next quarter according to experts. Let's dive in.

Investing.com -- Goldman Sachs initiated coverage on ResMed Inc (NYSE ... strong growth prospects in its continuous airway pressure (CPAP) therapy segment.

LLY is up 1.7% at $480.55 at last glance, while shares of rival ResMed Inc (NYSE:RMD), which creates continuous positive airway pressure (CPAP) devices for sleep apnea, was last seen down 5% at $ ...

ResMed is a leading manufacturer of Continuous Positive Airway Pressure (CPAP) devices, that are now standard treatments for OSA. ResMed also owns 4.62% of Nyxoah. Now both of these companies are ...